Thylmer Created By Fournier In Canada
Fournier Pharma of Canada, a subsidiary of the French group Fournier,has announced the creation of Thylmer, a new division specializing in the development and promotion of cardiovascular health products and drugs delivered through transdermal patch systems.
Thylmer will bring to Canada Fournier's expertise in cardiovascular medicine and drug delivery systems including hormone replacement therapy products, said the company. The division will employ around 40 staff to promote products in the areas of cardiovascular medicine and women's health, and to work with the Fournier division on the promotion of the lipid-lowering agent Lipidil Micro (micronized fenofibrate).
Sales of the product in Canada reached over C$35 million ($25.3 million) in 1996, and are expected to be significantly higher this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze